Katen out at Pfizer, Kelly's role unclear

Share this article:
Karen Katen will leave Pfizer, the company said. Katen, a 32-year Pfizer veteran who serves as vice chairman and president of the company's human health division, is stepping down after being passed over in favor of Jeff Kindler to replace Hank McKinnell as CEO. Vice Chairman David Shedlarz, also a contender for the top job, will remain on, taking on additional responsibilities including global manufacturing, worldwide strategic planning, licensing and business development and technology. Assuming Katen's duties will be European ops head Ian Read, who becomes worldwide pharmaceutical operations president. Also losing his post, according to The New York Times, is marketing innovator Pat Kelly, president of US pharmaceuticals. He is being replaced by Peter Brandt, the former area president for Latin America who was named EVP of US pharmaceuticals reporting to Kelly in March. Pfizer did not return phone calls from MM&M, and it remains unclear whether Kelly will stay with the company in a new role. Word of the moves came with the announcement of a new leadership organization consisting of: Shedlarz; Read; Global Research and Development President John LaMattina; Chief Medical Officer Dr. Joe Feczko; Worldwide Talent Development and Human Resources head Sylvia Montero; General Counsel Allen Waxman and Worldwide Public Affairs and Policy leader Rich Bagger. Katen will remain on for several months to advise the company on healthcare policy and the firm's Health Solutions and Healthy Directions initiatives.
Share this article:
close

Next Article in Industry News

Email Newsletters